Skip to main content

Table 3 Baseline characteristics among the 66 patients who received palliative systemic treatment

From: Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

Characteristic

Frequency

%

 

Median (years)

54 (range, 22-78)

Age

<60

42

63.6

 

≥ 60

24

36.4

Sex

Male

41

62.1

 

Female

25

37.9

 

Absent

61

92.4

Carcinoid symptom

Present

3

4.5

 

Unavailable

2

3.0

 

Pancreas

2

3.0

 

GI

15

22.7

Origin

Lung

15

22.7

 

Etc.*

22

33.3

 

Unknown

12

18.2

 

Local

10

15.2

Prior stage

Regional

9

13.6

 

Distant

47

71.2

Grade

1

20

30.3

 

2

1

1.5

 

3

10

15.2

 

Large

8

12.1

 

Small

5

7.6

 

Unclassified

15

22.7

 

Unavailable

7

10.6

 

24-hour urine 5-HIAA (μmol/day)†

Median (range)

33.5 (6.8-341.2)

  

<31.4

5

45.5%

Biomarkers

 

≥ 31.4

6

54.5%

  

Median (range)

1.36 (0.2-23.1)

 

Serum NSE (nmol/l)‡

<1.0

8

36.4%

  

≥ 1.0

14

63.6%

  1. Abbreviations as in table 1, 2
  2. *The uterus (4 cases), biliary tract (3), thymus (3), mediastinum (2), oral cavity (2), skin (2), trachea (1), kidney (1), prostate (1), bladder (1), nasal cavity (1), and orbit (1)
  3. † Available data: 11
  4. ‡ Available data: 22
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us